Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study-Reference-Cited by-同舟云学术

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Published:2022-06-24 Issue:5 Volume:16 Page:1150-1160
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Hatanaka Takeshi^ORCID,Kakizaki Satoru^ORCID,Hiraoka Atsushi,Tada Toshifumi,Hirooka Masashi,Kariyama Kazuya,Tani Joji,Atsukawa Masanori,Takaguchi Koichi,Itobayashi Ei,Fukunishi Shinya,Tsuji Kunihiko,Ishikawa Toru,Tajiri Kazuto,Ochi Hironori,Yasuda Satoshi,Toyoda Hidenori,Ogawa Chikara,Nishimura Takashi,Shimada Noritomo,Kawata Kazuhito,Kosaka Hisashi,Tanaka Takaaki,Ohama Hideko,Nouso Kazuhiro,Morishita Asahiro,Tsutsui Akemi,Nagano Takuya,Itokawa Norio,Okubo Tomomi,Arai Taeang,Imai Michitaka,Naganuma Atsushi^ORCID,Koizumi Yohei,Nakamura Shinichiro,Joko Kouji,Kaibori Masaki,Iijima Hiroko,Hiasa Yoichi,Kumada Takashi,

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-022-10358-z.pdf

Reference56 articles.

1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905

2. Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–4345

3. Vogel A, Martinelli E. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32:801–805

4. Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology. 2021;73(Suppl 1):158–191

5. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492–2502

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

2. CRAFITY score benefits hepatocellular carcinoma patients treated with transarterial chemoembolization and lenvatinib;Cancer Medicine;2024-06

3. Efficacy and safety of stereotactic radiotherapy on elderly patients with stage I-II central non-small cell lung cancer;Frontiers in Oncology;2024-05-13

4. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real‐world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial;Alimentary Pharmacology & Therapeutics;2024-05-08

5. CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils;Journal of Hepatocellular Carcinoma;2024-05